摘要
目的 观察胰激酞原酶对 2型糖尿病合并肾病患者尿白蛋白排出率 (UAER)的影响。方法 选择1 2 0例 2型糖尿病病人 ,按尿白蛋白排出率分为大量白蛋白尿组、微量白蛋白尿组和正常白蛋白尿 3组 ,每组随机分为治疗组和对照组。在原治疗基础上 ,治疗组加用口服胰腺激酞原酶 8周 ,测定服药前后UAER的变化。结果 大量白蛋白尿组及微量白蛋白尿组治疗组UAER均较对照组明显下降 (P <0 0 1 )。正常白蛋白尿组治疗组较对照组无明显变化 (P >0 0 5 )。结论 胰激酞原酶能明显降低 2型糖尿病患者尿白蛋白的排出 ,从而预防或延缓
Objective To observe the effects of pancreatic kininogenase on the urine albumin excretory rate (UAER) of type Ⅱ diabetes mellitus (T2DM) accompanying nephrosis. Methods 120 T2DM patients were divided into 3 groups randomly including the mass albuminuria group, the trace albuminuria group and normal albuminuria group. Each group would be further divided into therapy group and control group. The therapy group would take orally pancreatic kininogenase additionally for 8 weeks on the basis of original therapy schem and UAER before and after taking the medicine would be measured. Results The UAER of the mass albuminuria therapy group and the trace albuminuria therapy group was dropped obviously than that in corresponding control groups (P<0.01). While the UAER of the normal albuminuria therapy group was not changed comparing with the normal control group (P>0.05). Conclusion Pancreatic kininogenase could decrease the excretory of urine albumin of T2DM patients so that could prevent or postpone the process of diabetic nephropathy.
出处
《黑龙江医学》
2004年第3期185-187,共3页
Heilongjiang Medical Journal
关键词
内科学
糖尿病肾病
胰激肽原酶
尿白蛋白排出率
Diabetic nephropathy
Pancreatic kininogenase
Urine albumin excretory rate